# CALGB 100104 (NCT00114101)

> Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

No report yet. It can be ordered.

- Drugs tested: lenalidomide
- Indication: multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00114101
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma; Refractory Multiple Myeloma; Smoldering Multiple Myeloma
- Interventions: Autologous Hematopoietic Stem Cell Transplantation; Laboratory Biomarker Analysis; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; Placebo Administration
- Enrollment: 460
- Primary outcome: Time to Progression

## Indexed commentary on CALGB 100104 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 29 posts on X
- 1 YouTube video

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=calgb-100104-nct00114101

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00114101", "email": "<work email>"}; the inbox owner confirms by the emailed link.
